Published in Cell Death Dis on May 14, 2015
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS One (2016) 1.47
Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol (2017) 1.40
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer (2016) 1.01
The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle (2015) 0.91
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology (2016) 0.84
Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology (2016) 0.79
Relevance of necroptosis in cancer. Immunol Cell Biol (2016) 0.78
The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology (2016) 0.76
A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. Oncotarget (2016) 0.76
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Front Immunol (2016) 0.75
Reassessing the role of NAD as a prosurvival factor. Mol Cell Oncol (2015) 0.75
Full Length Interleukin 33 Aggravates Radiation-Induced Skin Reaction. Front Immunol (2017) 0.75
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 7.46
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol (2005) 5.04
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med (1998) 4.08
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem (1998) 3.80
Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell (2003) 3.68
Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol (2010) 3.51
Apoptosis and caspases in neurodegenerative diseases. N Engl J Med (2003) 3.40
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A (2006) 3.19
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity (2013) 3.15
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2006) 2.44
Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ (2009) 2.33
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 1.62
zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFα mediated by the PKC-MAPKs-AP-1 pathway. Cell Death Differ (2010) 1.54
The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol (2006) 1.53
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (2011) 1.41
Dendritic cells in the cancer microenvironment. J Cancer (2012) 1.40
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A (2011) 1.36
Functions of toll-like receptors: lessons from KO mice. C R Biol (2004) 1.36
Immune response against dying tumor cells. Adv Immunol (2004) 1.26
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ (2007) 1.24
Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother (2008) 1.18
Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia (1996) 1.18
Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol (2006) 1.16
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
Clearance deficiency--a potential link between infections and autoimmunity. Autoimmun Rev (2008) 1.09
Autophagy and ionizing radiation in tumors: the "survive or not survive" dilemma. J Cell Physiol (2013) 1.07
Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther (2010) 1.07
The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys (2011) 1.04
Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia (2012) 1.04
High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal (2011) 1.03
High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res (2010) 1.02
Tumor stress, cell death and the ensuing immune response. Cell Death Differ (2007) 1.01
Generation, culture and flow-cytometric characterization of primary mouse macrophages. Methods Mol Biol (2009) 1.00
The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol (2012) 0.99
The translocation of nuclear molecules during inflammation and cell death. Antioxid Redox Signal (2013) 0.96
Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis (2014) 0.95
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res (2006) 0.93
Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol (2011) 0.92
Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis (2012) 0.90
Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J Immunother (2008) 0.90
Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Mol Cancer Ther (2009) 0.89
How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol (2012) 0.88
Kinetic effects of Ca2+ and Mg2+ on ATP hydrolysis by the purified ATP diphosphohydrolase. J Biol Chem (1982) 0.85
Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters. Clin Transl Oncol (2012) 0.83
Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI. Natl Cancer Inst Monogr (1977) 0.83
Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury. PLoS One (2010) 0.83
Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol (2012) 0.82
OncoImmunology: a new journal at the frontier between oncology and immunology. Oncoimmunology (2012) 0.82
Extracellular adenosine metabolism in immune cells in melanoma. Cancer Immunol Immunother (2014) 0.82
Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine. Cryobiology (2013) 0.76